Cincinnati Children’s Becomes Seventh U.S. Center Authorized to Deliver ZEVASKYN for RDEB Patients

As reported by The Manila Times, Abeona Therapeutics has announced that Cincinnati Children’s Hospital Medical Center has been designated as the seventh Qualified Treatment Center (QTC) authorized to administer ZEVASKYN®…

Continue Reading Cincinnati Children’s Becomes Seventh U.S. Center Authorized to Deliver ZEVASKYN for RDEB Patients

Epidermolysis Bullosa Care Enters a New Era With Gene-Targeted and Wound-Healing Therapies

An article from Medscape highlighted recent advances in treatment that are reshaping the clinical approach to epidermolysis bullosa (EB), transitioning care from largely supportive management to therapies that address genetic…

Continue Reading Epidermolysis Bullosa Care Enters a New Era With Gene-Targeted and Wound-Healing Therapies

Solving Cell Therapy’s Dirty Secret: How One Partnership Could Unlock Consistent Treatments

Mesenchymal stromal cells (MSCs) have tantalized the medical world for years. These versatile immune-modulating cells offer genuine hope for diseases ranging from epidermolysis bullosa, a genetic disorder where skin tears…

Continue Reading Solving Cell Therapy’s Dirty Secret: How One Partnership Could Unlock Consistent Treatments
Congressman George Santos Apparently Lied About Helping Kids Living with Epidermolysis Bullosa
source: unsplash.com

Congressman George Santos Apparently Lied About Helping Kids Living with Epidermolysis Bullosa

According to a story from VICE News, Congressman George Santos was recently elected to Congress in the 2022 mid-term elections. Since then, his past has been placed under scrutiny, and…

Continue Reading Congressman George Santos Apparently Lied About Helping Kids Living with Epidermolysis Bullosa
Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval
source: pixabay.com

Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval

According to a story from prnewswire.com, the biopharmaceutical company InMed Pharmaceuticals, Inc. has recently announced that that company's Clinical Trial Application has been approved in the Netherlands. This approval will…

Continue Reading Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval

Results From First Patient Treated in Epidermolysis Bullosa Phase 2 Trial are Extremely Promising

Epidermolysis Bullosa Epidermolysis bullosa (EB) is a rare condition affecting approximately 500,000 individuals globally. Patients in the United States and Europe account for 50,000 of these individuals. The hereditary condition is…

Continue Reading Results From First Patient Treated in Epidermolysis Bullosa Phase 2 Trial are Extremely Promising